Skip to main content
Premium Trial:

Request an Annual Quote

Life Technologies Confirms Closure of ABI's Connecticut Corporate Offices

NEW YORK (GenomeWeb News) – Life Technologies, the recently merged combination of Invitrogen and Applied Biosystems, confirmed for GenomeWeb Daily News today that it will close ABI’s corporate offices in Norwalk, Conn., as part of efforts to eliminate redundant operations.
The firm will shutter the facility in July 2009, and corporate functions at that site will be transitioned to other locations between this month and then, according to a Life Technologies spokesperson. The firm did not disclose how many positions would be eliminated as part of the closure, but several local media outlets in Connecticut reported that around 100 jobs will be lost as a result. Life Technologies also has not disclosed how many jobs would be transferred to other offices.
In advance of the completion of the merger, Invitrogen said in October that it expects $80 million in synergies, mostly from cost savings, in the first year after closing the deal. Part of those synergies were expected to come from corporate overhead reductions, “which unfortunately does include the elimination of redundant positions between the two companies,” the spokesperson said in an e-mail today.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.